Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Ligand Pharmaceuticals's EV/EBITDA was 38.2× on Nov 11, 2026, against 63.8× a year earlier. Over the last 5 years it ranged from 7.8× to 164.6×, with a median of 24.3×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 38.2× | −20.3 |
| 2025 | Dec 31, 2025 | 58.5× | −34.7 |
| 2024 | Dec 31, 2024 | 93.3× | +62.2 |
| 2023 | Dec 29, 2023 | 31.0× | +22.2 |
| 2022 | Dec 30, 2022 | 8.8× | −7.3 |
| 2021 | Dec 31, 2021 | 16.1× | −17.7 |
| 2020 | Dec 31, 2020 | 33.8× | +23.1 |
| 2019 | Apr 30, 2019 | 10.7× | +0.3 |
| 2018 | Dec 31, 2018 | 10.4× | −28.1 |
| 2017 | Dec 29, 2017 | 38.6× | −6.3 |
| 2016 | Dec 30, 2016 | 44.9× | −24.2 |
| 2015 | Dec 31, 2015 | 69.1× | +22.9 |
| 2014 | Dec 31, 2014 | 46.3× | −26.4 |
| 2013 | Dec 31, 2013 | 72.6× | −95.7 |
| 2012 | Dec 31, 2012 | 168.3× | – |
See a number that looks wrong?